+0.02 (+5.11%)
Dilution Risk
Revenue
56.33 K
R&D Expenses
793.98 K
Operating CF
-2.92 M
Total Assets
80.66 M
Total Liabilities
13.84 M
Equity
66.82 M
D/E Ratio
12,345
Cash Position
3.54 M
Monthly Burn
973.00 K
Runway
3 mo
Burn Trend
StableSEC Filing
May 15, 2026locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Submission example | SCN-102 Migraine | NDA | — | Small Molecules | Nervous System | ||
NDA Submission example | SCN-102 Migraine | NDA | — | Small Molecules | Nervous System | ||
NDA Submission example | SCN-102 Migraine | NDA | — | Small Molecules | Nervous System |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||